id: NEW:kratom_access_availability_to_opioid_use_disorder
name: Kratom Access and Availability â†’ Opioid Use Disorder
from_node:
  node_id: NEW:kratom_access_availability
  node_name: Kratom Access and Availability
to_node:
  node_id: opioid_use_disorder
  node_name: Opioid Use Disorder
direction: negative
category: behavioral
mechanism_pathway:
- 'Step 1: Kratom contains alkaloids (mitragynine, 7-hydroxymitragynine) that act as partial mu-opioid
  receptor agonists'
- 'Step 2: These compounds produce opioid-like effects that may reduce opioid craving and withdrawal symptoms'
- 'Step 3: Individuals self-administer kratom as a substitute for more harmful opioids'
- 'Step 4: Reduced reliance on illicit opioids decreases progression and severity of opioid use disorder'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: MeShell Green et al. 2024. "Kratom as a potential substance use disorder harm reduction
    agent." https://doi.org/10.3389/fpubh.2024.1416689
  supporting_citations:
  - Historical use in Southeast Asia for opioid withdrawal management (described in review)
  - Early preclinical studies on kratom pharmacology (referenced in abstract)
  - Additional citations require full-text access
  doi: 10.3389/fpubh.2024.1416689
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Kratom's pharmacological properties as a partial mu-opioid agonist suggest potential for
  reducing opioid use disorder severity through substitution and withdrawal management, though evidence
  remains preliminary
spatial_variation:
  varies_by_geography: true
  variation_notes: Historically used in Southeast Asia for harm reduction; growing use in the US with
    different regulatory context
moderators:
- name: regulation_status
  direction: strengthens
  strength: moderate
  description: Limited regulation of kratom manufacturing and sale affects quality control and safety
- name: access_to_conventional_treatment
  direction: strengthens
  strength: strong
  description: Kratom use may be more prevalent among those lacking access to or reluctant to seek conventional
    MAT
structural_competency:
  equity_implications: This mechanism highlights how barriers to conventional SUD treatment (stigma, access,
    cost) may drive individuals toward unregulated alternatives like kratom. The lack of treatment access
    is a structural issue rooted in healthcare system failures, not individual choice.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.126217'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
